• Video
  • Shop
  • Culture
  • Family
  • Wellness
  • Food
  • Living
  • Style
  • Travel
  • News
  • Book Club
  • Newsletter
  • Privacy Policy
  • Your US State Privacy Rights
  • Children's Online Privacy Policy
  • Interest-Based Ads
  • Terms of Use
  • Do Not Sell My Info
  • Contact Us
  • © 2026 ABC News
  • Wellness

Infant Vaccine Against Meningitis Shows Promise

ByLIZ SZABOUSA TODAY
February 18, 2009, 4:59 PM

Jan. 9, 2008— -- An experimental vaccine appears to protect newborns from meningococcal disease, a major cause of meningitis.

Babies under 1 year are especially vulnerable to meningococcal disease. Infants this age have the highest rates of infection but aren't protected by an existing vaccine, which is approved only for children over 2.

Though this type of meningitis is relatively rare -- it afflicts only 1,400 to 2,800 Americans a year -- it can be devastating. Ten percent to 14 percent of patients die, and up to 20 percent of survivors develop long-term disabilities, such as brain damage, hearing loss or amputation, according to a study in today's Journal of the American Medical Association.

"It's one of the few infections left in the U.S. that can kill a healthy young person in only a couple of hours," says Lee Harrison, a professor of medicine and epidemiology at the University of Pittsburgh, who wrote an editorial accompanying the study.

Doctors hope an experimental shot from Novartis, called Menveo, will prevent much of that suffering. Researchers in Canada and the United Kingdom tested Menveo -- which targets four of five meningococcal bacteria strains -- in more than 400 babies, the study said. The study received funding from Novartis.

Babies need several doses of Menveo for long-term immunity. The vaccine was about 94 percent effective when given in four doses, one at 2 months, 3 months, 4 months and 12 months -- a dosing schedule that fits into standard vaccination programs in the U.K., says study author Matthew Snape, a pediatrician at the University of Oxford.

When given in three doses, one each at 2 months, 4 months and 12 months -- the standard pattern for shots in the USA -- the vaccine was 86 to 100 percent effective, providing more protection against some strains of the bacteria than others, Snape says.

If approved, a meningococcal vaccine could prevent half of the roughly 300 cases of meningococcal meningitis in babies under 2, says Amanda Cohn, a pediatrician at the Centers for Disease Control and Prevention.

Up Next in Wellness—

3 Connecticut children die from apparent diphenhydramine overdoses, no confirmed link to viral 'Benadryl challenge'

June 10, 2026

FDA green-lights 1st new sunscreen ingredient in years

June 9, 2026

Doctor breaks down study showing GLP-1s may lower breast cancer risk

June 3, 2026

Identical twin doctors return to lead hometown hospital ER

June 3, 2026

Shop GMA Favorites

ABC will receive a commission for purchases made through these links.

Sponsored Content by Taboola

The latest lifestyle and entertainment news and inspiration for how to live your best life - all from Good Morning America.
  • Contests
  • Terms of Use
  • Privacy Policy
  • Do Not Sell My Info
  • Children’s Online Privacy Policy
  • Advertise with us
  • Your US State Privacy Rights
  • Interest-Based Ads
  • About Nielsen Measurement
  • Press
  • Feedback
  • Shop FAQs
  • ABC News
  • ABC
  • All Videos
  • All Topics
  • Sitemap

© 2026 ABC News
  • Privacy Policy— 
  • Your US State Privacy Rights— 
  • Children's Online Privacy Policy— 
  • Interest-Based Ads— 
  • Terms of Use— 
  • Do Not Sell My Info— 
  • Contact Us— 

© 2026 ABC News